Protara Therapeutics, Inc. TARA shares are down during Tuesday’s premarket session following the release of updated interim ...

The company reported strong efficacy and a clean safety profile from its ongoing Phase 2 Advanced-2 bladder cancer trial.

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor ...

As of Tuesday, February 24, Burning Rock Biotech Limited’s BNR share price has dipped by 6.28%, which has investors questioning if this is right time to buy.

As of Monday, February 23, ImmunityBio, Inc.’s IBRX share price has surged by 20.31%, which has investors questioning if this ...

Protara Therapeutics has touted a 66% complete response (CR) rate for its cell therapy among certain bladder cancer patients ...

The interim analysis of the BCG-Unresponsive cohort includes 35 evaluable participants, of whom, 22 were evaluable at six months and 15 were evaluable at 12 months as of a January 28, 2026 data cutoff ...

Conference Call and Webcast Scheduled for Monday, March 2, 2026 at 10:00 AM ETPRINCETON, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to ...